Clinical Trials: Mantle Cell Lymphoma

Huntsville : Clearview Cancer Institute

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Huntsville : TG Therapeutics Investigational Trial Site

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Tucson : U Arizona Cancer Center

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Tucson : Arizona Cancer Center

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Duarte : City of Hope

A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma post Autologous Hematopoietic Cell Transplantation

View More »

Beverly Hills : Providence Health Services

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Los Angeles :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Los Angeles : UCLA

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Palo Alto : Stanford Cancer Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Stanford : Stanford Cancer Center - Stanford University

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Stanford :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Stanford : Stanford University School of Medicine

TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas

Aurora : Investigational Site Number 840004

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Norwalk :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Miami : University of Miami

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Augusta : Georgia Health Sciences University

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Augusta : Investigational Site Number 840006

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Chicago :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Peoria :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Goshen :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Indianapolis : Indiana University Simon Cancer Center

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Terre Haute : RHHP/ Hope Cancer Center

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Sioux City :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Lexington :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Lexington : Univ. of Kentucky Chandler Medical Center, Hematology/Oncology/BMT CRP, Markey Cancer Center

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Louisville :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Metairie :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Bethesda : Center for Cancer and Blood Disorders

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Boston : Dana-Farber Cancer Institute

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Boston : Massachusetts General Hospital

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Worcester :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Worcester : University of Massachusets Memorial Medical Center

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Ann Arbor :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Detroit :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Rochester : Mayo Clinic

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Chesterfield : St. Louis Cancer Care

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Jefferson City :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Saint Louis :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

St. Louis : Washington University School of Medicine

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Hackensack :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Hackensack : Research Site

AMG 319 Lymphoid Malignancy FIH

Hackensack : Hackensack University Medical Center

Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma

Morristown : Hematology-Oncology Associates of Northern NJ

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

New Brunswick : Investigational Site Number 840001

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

New Hyde Park : Long Island Jewish Medical Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

New York :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

New York : Weill Cornell Medical College

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

New York : Memorial Sloan-Kettering Cancer Center

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

New York : Memorial Sloan-Kettering Cancer Center

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

View More »

New York : Weill Medical College of Cornell

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

New York : Weill Cornell Medical College

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Rochester : University of Rochester

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Syracuse :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Chapel Hill : Division of Hematology-Oncology, UNC Chapel Hill Lineberger Comprehensive Cancer Center

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Durham : Research Site

AMG 319 Lymphoid Malignancy FIH

Bismarck : Legacy Pharma Research

Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant.

Columbus : The Ohio State University Comprehensive Cancer Center

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Springfield : Willamette Valley Cancer Institute and Research Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Charleston : Investigational Site Number 840002

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Watertown :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Chattanooga : Chattanooga Oncology Hematology Associates

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Nashville : Sarah Cannon Research Institute

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Nashville :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Nashville : Tennessee Oncology, PLLC

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Nashville : Sarah Cannon Research Institute

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Dallas : Mary Crowley Cancer Research Centers - Medical City

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Houston :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Houston : UT MD Anderson Cancer Center

Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma

Houston : The Methodist Cancer Center

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Houston : Investigational Site Number 840003

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

View More »

Houston : UT MD Anderson Cancer Center

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Houston : MD Anderson Cancer

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

San Antonio : University of Texas Health Science Center at San Antonio

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Burlington :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Charlottesville : University of Virginia Health System

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Seattle : Seattle Cancer Care Alliance

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Yakima : North Star Lodge Cancer Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Morgantown : West Virginia University - Clinical Trials Research Unit

C18083-3064/NL/MN - An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

View More »

Morgantown :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Madison : University of Wisconsin

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Melbourne : Peter MacCallum Cancer Centre

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)

Brugge :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Gent :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Gent :

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Hamilton : Juravinski Cancer Centre at Hamilton Health Sciences

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Montreal : McGill University - Dept. Oncology

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Regina : Allan Blair Cancer Centre

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Toronto : Univ. Health Network-Princess Margaret Hospital

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Brno-Bohunice : FN Brno

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Hradec Králové : Fakultni nemocnice Hradec Kralove

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Praha : Charles University General Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Copenhagen : Rigshospitalet, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Helsinki : Helsinki University Central Hospital

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Grenoble : Valerie ROLLAND NEYRET

Study of Mantle Cell Lymphoma Treatment by RiBVD

Lille : CHRU- Hôpital Claude Huriez

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Mulhouse N/A :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Nantes Cedex 1, : CHRU - Hotel Dieu, Hématologie

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Nantes N/A :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

View More »

Nice Cedex 1 : Centre Antoine Lacassagne

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Pessac :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Rennes Cedex : CHU de Rennes Hôpital de Pontchaillou

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Vandoeuvre Les Nancy :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Essen : Universitätsklinikum Essen

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Freiburg : Universitätsklinikum Freiburg - Medizinische Klinik

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Göttingen : UKG Universitätsklinikum Göttingen

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Mainz : Universitätsmedizin Mainz

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Ulm : Universitätsklinikum Ulm

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Budapest :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Debrecen :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Gyor :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Kaposvar :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Miskolc :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

View More »

Szeged :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Hadera :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Haifa :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Petah Tikva :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Ramat Gan :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Oslo : Norwegian Radium Hospital

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Stavanger : University Hospital of Stavanger, Department of Haematology and Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Chorzow :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Lodz :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Warszawa : Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie w Warszawie

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Wrocław : S.P. Szpital Kliniczny Nr1, Klinika Hematologii Nowotworów Krwi i Transplantacji Szpiku, ul. Pasteura

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Wrocław : Szpital Kliniczny Nr1

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

San Juan :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Kazan : Republic Clinical Oncology Dispensary

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Moscow : Blokhin Cancer Research Center

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Nizhny Novgorod :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Rostov-Na-Donu :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

St. Petersburg : St. Petersburg Pavlov State Medical University Hematology Center

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

View More »

St. Petersburg : St. Petersburg Research Institute of Hematology and Blood Transfusion

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

St. Petersburg : Federal State Institution "Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies named after V.A. Almazov"

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

St.-Petersburg :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

St-Petersburg :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Volgograd : State Healthcare Institution "Volgograd Regional Clinical OncologyDispensary #1"

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Yekaterinburg : State Healthcare Institution "Sverdlovsk Regional Clinical Hospital #1"

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Barcelona :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Salamanca :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Göteborg : Sahlgrenska University Hospital, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Linköping : University Hospital Linköping, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Luleå : Sunderbyn Hospital, Department of Medicine

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Lund : University Hospital Lund, Department of Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Lund :

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

View More »

Stockholm : Karolinska University Hospital, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Sundsvall : Sundsvall Hospital, Department of Medicine

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Umeå : University Hospital of Norrland, Department of Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Uppsala : Uppsala University Hospital, Department of Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Dorset, : The Royal Bournemouth Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

London :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

London : King's College Hospital

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

London : University College London

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Manchester : Christie Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

View More »

Manchester : The Christie NHS Foundation

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Newcastle upon Tyne : Newcastle Hospitals Foundation Trust, Royal Victoria Infirmary

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Newcastle upon Tyne : University of Newcastle Upon Tyne, NHS Foundation Trust

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Plymouth : Derriford Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Plymouth :

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy